Cargando…

Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series

The Nottingham Prognostic Index Plus (NPI+) is a clinical decision making tool in breast cancer (BC) that aims to provide improved patient outcome stratification superior to the traditional NPI. This study aimed to validate the NPI+ in an independent series of BC. Eight hundred and eighty five prima...

Descripción completa

Detalles Bibliográficos
Autores principales:	Green, Andrew R, Soria, Daniele, Stephen, Jacqueline, Powe, Desmond G, Nolan, Christopher C, Kunkler, Ian, Thomas, Jeremy, Kerr, Gillian R, Jack, Wilma, Cameron, David, Piper, Tammy, Ball, Graham R, Garibaldi, Jonathan M, Rakha, Emad A, Bartlett, John MS, Ellis, Ian O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858129/ https://www.ncbi.nlm.nih.gov/pubmed/27499914 http://dx.doi.org/10.1002/cjp2.32

Ejemplares similares

Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer
por: Rakha, E A, et al.
Publicado: (2014)

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer
por: Green, Andrew R., et al.
Publicado: (2016)

Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification
por: Powe, Desmond G, et al.
Publicado: (2009)

Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers
por: Green, A R, et al.
Publicado: (2013)

Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation
por: Kwok, T’ng Chang, et al.
Publicado: (2010)

Identification and definition of novel clinical phenotypes of breast cancer through consensus derived from automated clustering methods
por: Green, AR, et al.
Publicado: (2008)

Smallpox at Nottingham
Publicado: (1921)

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
por: Aleskandarany, Mohammed, et al.
Publicado: (2015)

Mammostrat(® )as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
por: Bartlett, John MS, et al.
Publicado: (2010)

The General Hospital, Nottingham
por: Reely, E. M.
Publicado: (1886)

The Nottingham General Hospital
Publicado: (1892)

The Children's Hospital at Nottingham
Publicado: (1899)

Children's Hospital, Nottingham
Publicado: (1899)

Children's Hospital, Nottingham
por: Morrish, Catherine A.
Publicado: (1899)

Children's Hospital, Nottingham
por: Morrish, T. Fox
Publicado: (1899)

Children's Hospital, Nottingham
por: Thompson, Geoffrey W.
Publicado: (1899)

Nottingham Children's Hospital
por: Floyd, Lettice A.
Publicado: (1899)

Children's Hospital, Nottingham
Publicado: (1899)

Nottingham Children's Hospital
Publicado: (1899)

Medical Report for Nottingham
por: Clarke, James
Publicado: (1812)

Medical Report for Nottingham
por: Clarke, James
Publicado: (1810)

Medical Report for Nottingham
por: Clarke, James
Publicado: (1811)

Regional Conference in Nottingham
por: Pavord, I D, et al.
Publicado: (1995)

Death of Dr. Nottingham
Publicado: (1876)

8th Nottingham International Breast Cancer Conference, Nottingham, UK, 16–19 September 2003
por: Limer, Jane L, et al.
Publicado: (2004)

The development of orthopaedics in the Nottingham area
por: Dickson, J. W.
Publicado: (1989)

The Nottingham and Midland Eye Infirmary
Publicado: (1912)

The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes
por: El Ansari, Rokaya, et al.
Publicado: (2018)

Biological and clinical significance of PARP1 protein expression in breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer–a targeted molecular approach
por: Green, William JF, et al.
Publicado: (2016)

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours
por: El Ansari, Rokaya, et al.
Publicado: (2018)

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
por: Green, Andrew R, et al.
Publicado: (2016)

Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients
por: Martin, Stewart G., et al.
Publicado: (2018)

Connexin 43 is an independent predictor of patient outcome in breast cancer patients
por: Chasampalioti, Maria, et al.
Publicado: (2018)

Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival
por: Powe, Desmond G., et al.
Publicado: (2010)

DACH1: Its Role as a Classifier of Long Term Good Prognosis in Luminal Breast Cancer
por: Powe, Desmond G., et al.
Publicado: (2014)

Retrospective assessment of cyclin‐dependent kinase 5 mRNA and protein expression and its association with patient survival in breast cancer
por: Saidy, Behnaz, et al.
Publicado: (2020)

The first Nottingham Medical School: 1833-1835?
por: Merskey, H
Publicado: (1968)

Visit to Messrs Etelco Instruments Div., Nottingham
Publicado: (1958)

Report from the General Hospital near Nottingham
por: Clarke, James
Publicado: (1807)

Cannot write session to /tmp/vufind_sessions/sess_9673in95e12o1vrvl6136vlm40